An Assessment of Progress in the Use of Alternatives in Toxicity Testing since the Publication of the Report of the Second FRAME Toxicity Committee (1991)
Restricted accessResearch articleFirst published online July, 2002
An Assessment of Progress in the Use of Alternatives in Toxicity Testing since the Publication of the Report of the Second FRAME Toxicity Committee (1991)
AnnettB. (1995). The Fund for the Replacement of Animals in Medical Experiments (FRAME): the first 25 years. ATLA23, 19–32.
2.
Anon. (1982). Report of the FRAME Toxicity Committee. ATLA10, 4–43.
3.
BallsM., RiddellR.J., & WordenA.N. eds (1983). Animals and Alternatives in Toxicity Testing, 550 pp. London & New York: Academic Press.
4.
Anon. (1991). Animals and alternatives in toxicology: present status and future prospects (The second report of the FRAME Toxicity Committee). ATLA19, 116–138.
5.
BallsM., BridgesJ., & SoutheeJ. eds (1991). Animals and Alternatives in Toxicology: Present Status and Future Prospects, 390 pp. London: Macmillan Press & New York: VCH Publishers.
6.
FestingM.F.W., BaumansV., CombesR.D., HalderM., HendriksenC.F.M., HowardB.R., LovellD.P., MooreG.J., OverendP., & WilsonM.S. (1998). Reducing the use of laboratory animals in biomedical research: problems and possible solutions. The report and recommendations of ECVAM workshop 29. ATLA26, 283–301.
7.
SpielmannH., BallsM., BrandM., DoringB., HolzhutterH-G., KalweitS., KlecakG., L'EplattenierH., LiebschM., LovellW.W., MaurerT., MoldenhauerF., MooreL., PapeW.J.W., PfannenbeckerU., PotthastJ., De SilvaO., SteilingW., & WillshawA. (1994). EEC/COLIPA project on in vitro phototoxicity testing: First results obtained with a Balb/c 3T3 cell phototoxicity assay. Toxicology in Vitro8, 793–796.
8.
SpielmannH., BallsM., DupuisJ., PapeW.J., PechovitchG., de SilvaO., HolzhutterH-G., ClothierR., DesolleP., GerberickF., LiebschM., LovellW.W., MaurerT., PfannenbeckerU., PotthastJ.M., CsatoM., SladowskiD., SteilingW., & BrantomP. (1998). The international EU/COLIPA in vitro phototoxicity validation study: results of phase II (blind trial). Part 1: the 3T3 NRU phototoxicity test. Toxicology in Vitro12, 305–327.
9.
SpielmannH., BallsM., DupuisJ., PapeW.J.W., de SilvaO., HolzhutterH-G., GerberickF., LiebschM., LovellW.W., & PfannenbeckerU. (1998). A study on UV filter chemicals from Annex VII of European Union Directive 76/768/EEC, on the in vitro 3T3 NRU phototoxicity test. ATLA26, 679–708.
10.
BallsM., BlaauboerB.J., FentemJ.H., BrunerL., CombesR.D., EkwallB., FielderR.J., GuillouzoA., LewisR.W., LovellD.P., ReinhardtC.A., RepettoG., SladowskiD., SpielmannH., & ZuccoF. (1995). Practical aspects of the validation of toxicity test procedures. The report and recommendations of ECVAM workshop 5. ATLA23, 123–147.
11.
OECD (1996). Final Report of the OECD Workshop on Harmonization of Validation and Acceptance Criteria for Alternative Toxicological Test Methods, 60 pp. Paris, France: OECD.
12.
FentemJ.H., ArcherG.E.B., BallsM., BothamP.A., CurrenR.D., EarlL.K., EsdaileD.J., HolzhutterH-G., & LiebschM. (1998). The ECVAM international validation study on in vitro tests for skin corrosivity. 2. Results and evaluation by the management team. Toxicology in Vitro12, 483–524.
13.
FentemJ.H., BriggsD., ChesneC., ElliottG.R., HarbellJ.W., HeylingsJ.R., PortesP., RoguetR., van de SandtJ.J.M., & BothamP.A. (2001). A prevalidation study on in vitro tests for acute skin irritation: results and evaluation by the Management Team. Toxicology in Vitro15, 57–93.
14.
NIH (1999). Evaluation of the Validation Status of Toxicological Methods: General Guidelines for Submissions to ICCVAM (Revised, October 1999). NIH Publication 99–4496, 44 pp. Research Triangle Park, NC, USA: NIEHS.
15.
CurrenR.D., SoutheeJ.A., SpielmannH., LiebschM., FentemJ.H., & BallsM. (1995). The role of prevalidation in the development, validation, and acceptance of alternative methods. ECVAM prevalidation task force report 1. ATLA23, 211–217.
16.
BrantomP.G., BrunerL.H., ChamberlainA., De SilvaO., DupuisJ., EarlL.K., LovellD.P., PapeW.J.W., & UttleyM. (1997). Summary report of the COLIPA international validation study on alternatives to the Draize rabbit eye irritation test. Toxicology in Vitro11, 141–179.
17.
BallsM., BothamP.A., BrunerL.H., & SpielmannH. (1995). The EC/HO international validation study on alternatives to the Draize eye irritation test. Toxicology in Vitro9, 871–929.
KimberI., & WeisenbergerC. (1989). A murine local lymph node assay for the identification of contact allergens: assay development and results of an initial validation study. Archives of Toxicology63, 274–282.
De SilvaO, BasketterD.A., BarrattM.D., CorsiniE., CroninM.T.D., DasP.K., DegwertJ., EnkA., GarrigueJ.L., HauserC., KimberI., LepoittevinJ-P., PeguetJ., & PonecM. (1995). Alternative methods for skin sensitisation testing: the report and recommendations of ECVAM workshop 19. ATLA24, 683–705.
22.
Anon. (1992). Commission Directive 92/69/EEC of 31 July 1992 adapting to technical progress for the seventeenth time Council Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances. Official Journal of the European CommunitiesL383, 1–235.
23.
Anon. (1996). Commission Directive 96/54/EC of 30 July 1996 adapting to technical progress for the twenty-second time Council Directive 67/548/EEC on the approximation of the laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances. Official Journal of the European CommunitiesL248, 1–230.
24.
Anon. (1998). Commission Directive 98/73/EC of 18 September 1998 adapting to technical progress for the 24th time Council Directive 67/548/EEC on the approximation of the laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances. Official Journal of the European CommunitiesL305, 1–181.
25.
Anon. (2000). Commission Directive 2000/32/EC of 19 May 2000 adapting to technical progress for the 26th time Council Directive 67/548/EEC on the approximation of the laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances. Official Journal of the European CommunitiesL136, 1–89.
26.
Anon. (2000). Commission Directive 2000/33/EC of 25 April 2000 adapting to technical progress for the 27th time Council Directive 67/548/EEC on the approximation of laws, regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances. Official Journal of the European CommunitiesL136, 90–107.
27.
ECVAM. (1998). Statement on the scientific validity of the 3T3 NRU PT test (an in vitro test for phototoxic potential). ATLA26, 7–8.
28.
Anon. (1998). Opinion on in vitro methods to assess phototoxicity in the safety evaluation of cosmetic ingredients or mixtures of ingredients adopted by the plenary session of the SCCNPP of 25 November 1998. Web site http://europa.eu.int/comm/food/fs/sc/sccp/outcome_en.html (Accessed 6.8.02).
ICCVAM (1999). The Murine Local Lymph Node Assay: A Test Method for Assessing the Allergic Contact Dermatitis Potential of Chemicals/Compounds. NIH Publication No. 99–4494. Web site http://iccvam.niehs.nih.gov (Accessed 7.8.02).
31.
ECVAM. (2000). Statement on the validity of the local lymph node assay for skin sensitisation testing. ATLA28, 365–367.
32.
LumleyC.E., & van CauterenH. (1997). Harmonisation of international toxicity testing guidelines for pharmaceuticals: contribution to refinement and reduction in animal use. European Biomedical Research Association Bulletin, November, 1997, pp. 4–9.
33.
SpielmannH., & LiebschM. (2001). Lessons learned from validation of in vitro toxicity tests: from failure to acceptance into regulatory practice. Toxicology in Vitro15, 585–590.
34.
SpielmannH. (2001). International co-operation: an essential requirement for replacing animal toxicity tests. ATLA29, 635–648.
35.
Commission of the European Communities (1991). Collaborative study on the evaluation of alternative methods to the eye irritation test. EC document XI/632/91, V/E/1/131/91. Luxembourg: CEC.
36.
CooperK.J., EarlL.K., HarbellJ., & RaabeH. (2001). Prediction of ocular irritancy of prototype shampoo formulations by the isolated rabbit eye (IRE) test and the bovine corneal opacity and permeability (BCOP) assay. Toxicology in Vitro15, 95–103.
37.
HaginoS., ItagakiH., KatoS., KobayashiT., & TankaM. (1991). Quantitative evaluation to predict the eye irritancy of chemicals: modification of chorioallantoic membrane test by using trypan blue. Toxicology in Vitro5, 301–304.
38.
JesterJ.V., LiL., MolaiA., & MaurerJ.K. (2001). Extent of initial corneal injury as a basis for alternative eye irritation tests. Toxicology in Vitro15, 115–130.
39.
GautheronP., GirouxJ., CottinM., AudegoundL., MorillaA., Mayordomo-BlancoL., TortajadaA., HaynesG., VericatJ.A., PirovanoR., Gillio TosE., HagemannC., VanparysP., DeknudtG., JacobsG., PrinsenM., KalweitS., & SpielmannH. (1994). Interlaboratory assessment of the bovine corneal opacity and permeability (BCOP) assay. Toxicology in Vitro8, 381–392.
40.
CombesR.D. (2000). The use of structure–activity relationships and markers of cell toxicity to detect nongenotoxic carcinogens. Toxicology in Vitro14, 387–399.
41.
KassG., & JonesR. (2000). Methods for assessing apoptosis. In Approaches to High Throughput Toxicity Screening (ed AtterwillC.K., GoldfarbP., & PurcellW.), pp. 107–138. London, UK: Taylor and Francis.
42.
GeorgeE, MurdockJ., AylottM., & WestmorelandC. (1999). Comparison of hepatocyte cultures and liver slices in in vitro toxicity testing. ATLA, 27, 769–781.
43.
GenestieI., MorinJ-P., GueryC., BodeG., & LorenzonG. (1997). Morphological and biochemical characterisation of primary culture of rabbit proximal kidney tubule cells grown on collagen IV coated Millicell-CM. In Vitro Cellular and Developmental Biology — Animal33, 692–702.
44.
MajumdarM.K., ThiedeM.A., MoscaJ.D., MoormanM., & GersonS.L. (1998). Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. Journal of Cellular Physiology176, 57–66.
45.
FielderR.J., AtterwillC.K., AndersonD., BoobisA.R., BothamP., ChamberlainM., CombesR., DuffyP., LewisR.W., LumleyC.E., KimberI., & NewallD.R. (1997). BTS working party report on in vitro toxicology. Human and Experimental Toxicology16, S1–S40.
46.
FreshneyI.R. (2000). Culture of Animal Cells: A Manual of Basic Techniques, 4th edn, 608 pp. Chichester, UK: Wiley.
47.
YoshitomiS., IkemotoK., TakahashiJ., MikiH., NambaM., & AsahiS. (2001). Establishment of the transformants expressing human cytochrome P450 subtypes in HepG2, and their applications on drug metabolism and toxicology. Toxicology in Vitro15, 245–256.
48.
BullS., LangezaalI., ClothierR., & CoeckeS. (2001). A genetically engineered cell-based system for detecting metabolism-mediated toxicity. ATLA29, 703–716.
49.
JoverR., BortR., Gomez-LechonM.J., & CastellJ.V. (1998). Re-expression of C/EBPα induces CYP26, CYP2C9 and CYP2D6 genes in HepG2 cells. FEBS Letters431, 227–230.
50.
AndersonR., O'HareM., BallsM., BradyM., BrahamsD., BurtA., ChesnéC., CombesR., DennisonA., GarthoffB., HawksworthG., KalterE., LechatA., MayerD., RogiersV., SladowskiD., SoutheeJ., TraffordJ., van der ValkJ., & van ZellerA-M. (1998). The availability of human tissue for biomedical research. The report and recommendations of ECVAM workshop 32. ATLA26, 763–777.
51.
AndersonR., BallsM., BurkeM.D., CumminsM., FehilyD., GrayN., de GrootM.G., HelinH., HuntC., JonesD., PriceD., RichertL., RavidR., ShuteD., SladowskiD., StoneH., ThaslerW., TraffordJ., van der ValkJ., WeissT., WomackC., & YlikomiT. (2001). The establishment of human research tissue banking in the UK and several western European countries. The report and recommendations of ECVAM workshop 44. ATLA29, 125–134.
52.
PfieferA.M.A., ColeK.E., SmootD.T., WestonA., GroopmanJ.D., ShieldsP.G., VignaudJ-M., JuilleratM., LipskyM.M., TrumpB., LechnerJ.F., & HarrisC.C. (1993). Simian virus 40 large tumor antigen–immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolise chemical carcinogens. Proceedings of the National Academy of Sciences, USA90, 5123–5127.
53.
CoeckeS., RogiersV., BaylissM., CastellJ., DoehmerJ., FabreG., FryJ., KernA., & WestmorelandC. (1999). The use of long-term hepatocyte cultures for detecting induction of drug metabolising enzymes: the current status. ECVAM hepatocytes and metabolically competent systems task force report 1. ATLA27, 579–638.
54.
OuelletteM.M., McDanielL., WrightW.E., ShayJ.W., & ShultzR. (2000). The establishment of telomerase-immortalized cell lines representing human chromosome instability syndromes. Human Molecular Genetics9, 403–411.
BarrattM.D., & BasketterD.A. (1994). Structure–activity relationships for skin sensitization: an expert system. In Alternative Methods in Toxicology, Vol. 10, In Vitro Skin Toxicology: Irritation, Phototoxicity, Sensitization (ed. RougierA., GoldbergA.M., & MaibachH.I.), pp. 293–301. New York, NY, USA: Mary Ann Liebert.
57.
BarrattM.D. (1997). QSARs for the eye irritation potential of neutral organic chemicals. Toxicology in Vitro11, 1–8.
58.
ChamberlainM., & BarrattM.D. (1995). Practical applications of QSAR to in vitro toxicology illustrated by consideration of eye irritation. Toxicology in Vitro9, 543–548.
59.
CombesR.D., & JudsonP. (1995). The use of artificial intelligence systems for predicting toxicity. Pesticide Science45, 179–194.
60.
DeardenJ.C., BarrattM.D., BenigniR., BristolD.W., CombesR.D., CroninM.T.D., JudsonP.M., PayneM.P., RichardA.M., TichyM., WorthA.P., & YourickJ.J. (1997). The development and validation of expert systems for predicting toxicity. The report and recommendations of an ECVAM/ECB workshop (ECVAM workshop 24). ATLA25, 223–252.
61.
CombesR.D. (2002). The use of expert systems for toxicity prediction. ATLA, in press.
62.
KlopmanG., & RosenkranzH.S. (1994). Approaches to SAR in carcinogenesis and mutagenesis. Prediction of carcinogenicity/mutagenicity using MULTI-CASE. Mutation Research305, 33–46.
63.
BenigniR. (2000). Structure-activity relationships in mutagenesis and carcinogenesis. In Progress in Reduction, Refinement and Replacement in Animal Experimentation (ed. BallsM., van ZellerA-M., & HalderM.E.), pp. 469–478. Amsterdam, The Netherlands: Elsevier Science.
64.
RidingsJ.E., BarrattM.D., CaryR., EarnshawC.G., EggingtonC.E., EllisM.K., JudsonP.N., LangowskiJ.J., MarchantC.A., PayneM.P., WatsonW.P., & YihT.D. (1996). Computer prediction of possible toxic action from chemical structure: an update on the DEREK system. Toxicology106, 267–279.
65.
LongA., & CombesR.D. (1995). Using DEREK to predict the activity of some carcinogens/mutagens found in foods. Toxicology in Vitro9, 563–569.
66.
BarrattM.D. (1998). Integrating computer prediction systems with in vitro methods towards a better understanding of toxicology. Toxicology Letters102-103, 617–621.
67.
GernerI., GraetschelG., KahlJ., & SchledeE. (1999). Development of a decision support system for the introduction of alternative methods into local irritancy/corrosivity testing strategies. Development of a relational database. ATLA28, 11–28.
68.
HowesD., GuyR., HadgraftJ., HeylingsJ., HoeckU., KemperF., MaibachH., MartyJ-P., MerkH., ParraJ., RekkasD., RondelliI., SchaeferH., TäuberU., & VerbieseN. (1996). Methods for assessing percutaneous absorption. The report and recommendations of ECVAM workshop 13. ATLA24, 81–106.
69.
BarrattM.D. (2000). Principles of toxicity prediction from chemical structure. In Progress in Reduction, Refinement and Replacement in Animal Experimentation (ed. BallsM., van ZellerA-M., & HalderM.E.), pp. 449–456. Amsterdam, The Netherlands: Elsevier Science.
70.
BarrattM.D., & RodfordR.A. (2001). The computational prediction of toxicity. Current Opinion in Chemical Biology5, 383–388.
71.
ToddM., GarthoffB., BernhardtW., BodéG., FarrS., KolarR., LumleyC., PietersM., RogiersV., SauerU., SpielmannH., StrausJ., & WarngardL. (1998). Issues relating to the release of proprietary information and data for use in the validation of alternative methods. The report and recommendations of ECVAM workshop 27. ATLA26, 13–20.
72.
LangleyG., BroadheadC., BottrillK., CombesR., EwbankR., HawkinsP., HubrechtR., JenningsM., NewmanC., RoweS., SoutheeJ., ToddM., & WardL. (1999). Accessing information on the reduction, refinement and replacement of animal experiments. ATLA27, 239–245.
73.
Anon. (2001). Information World Review, Issue 172, p. 18.
74.
BothamP., EarlL.K., FentemJ.H., RoquetR., & van der SandtJ.J.M. (1998). Alternative methods for skin irritation testing: the current status. ECVAM skin irritation task force report 1. ATLA26, 195–211.
75.
LumleyC.E., ParkinsonC., & WalkerS.R. (1993). A retrospective comparison of the results of six- and twelve-month non-rodent toxicity studies. Adverse Drug Reactions and Toxicological Reviews12, 53–61.
76.
BroadheadC., BettonG., CombesR.D., DammentS., EverettD., GarnerC., GodsafeZ., HealingG., HeywoodR., JenningsM., LumleyC., OliverG., SmithD., StraughanD., TophamJ., WallisR., & WilsonS. (2000). Prospects for reducing and refining the use of dogs in the regulatory toxicity testing of pharmaceuticals. Human and Experimental Toxicology19, 440–447.
77.
WorthA.P., BarrattM.D., & HoustonJ.B. (1998). The validation of computational prediction techniques. ATLA26, 241–247.
78.
BallsM., van ZellerA-M., & HalderM.E. eds (2000). Progress in Reduction, Refinement and Replacement in Animal Experimentation, 1795 pp. Amsterdam, The Netherlands: Elsevier Science.
79.
van der ValkJ., DewhurstD., HughesI., AtkinsonJ., BalcombeJ., BraunH., GabrielsonK., GruberF., MilesJ., NabJ., NardiJ., van WilgenburgH., ZinkoU., & ZurloJ. (1999). Alternatives to the use of animals in higher education. The report and recommendations of ECVAM workshop 33. ATLA27, 39–52.
80.
ZinkoU., JukesN., & GerickeC. (2001). From Guinea-pig to Computer Mouse: Alternative Methods for a Humane Education, 2nd edn. Leicester, UK: EuroNiche.
81.
EkwallB., ClemedsonC., CrafoordB., EkwallB., HallanderS., SjostromM., & WalumE. (1996). Correlation between in vivo and in vitro acute toxicity: preliminary results from the final MEIC evaluation. In Development of (Eco)toxicity Tests, Tema Nord Series (ed LouekariK., & TibergE.). Copenhagen, Denmark: Nordic Council of Ministers.
82.
EkwallB., ClemedsonC., EkwallB., RingP., & RomertL. (1999). EDIT: a new international multi-centre programme to develop and evaluate batteries of in vitro tests for acute and chronic systemic toxicity. ATLA27, 339–349.
83.
EkwallB. (1999). Overview of the final MEIC results. II. The in vitro–in vivo evaluation. Including the selection of a practical battery of cell tests for prediction of acute lethal blood concentrations in humans. Toxicology in Vitro13, 665–673.
84.
Anon. (1986). Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Official Journal of the European CommunitiesL358, 1–29.
85.
ICH (1997). ICH Harmonised Tripartite Guideline: Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals, 12 pp. Geneva, Switzerland: ICH Secretariat. Web site http://www.ich.org/pdflCH/s2b.pdf (Accessed 8.8.02).
86.
Anon. (1992). EC Council Directive of 30 April 1992 amending for the seventh time Directive 67/548/ EEC on the approximation of the laws regulations and administrative provisions relating to the classification, packaging and labelling of dangerous substances (92/32/EEC). Official Journal of the European CommunitiesL154, 05–06-92.
87.
Anon. (1993). Council Regulation (EEC) No. 793/93 of 23 March 1993 on the evaluation and control of risks of existing substances (793/93/EEC). Official Journal of the European CommunitiesL84, 1–75.
88.
BallsM., De KlerckW., BakerF., van BeekM., BouillonC, BrunerL., CarstensenJ., ChamberlainM., CottinM., CurrenR., DupuisJ., Fair-weatherF., FaureU., FentemJ., FisherC., GalliC., KemperF., KnaapA., LangleyG., LoprienoG., LoprienoN., PapeW., PechovitchG., SpielmannH., UngarK., WhiteI., & ZuangV. (1995). Development and validation of non-animal tests and testing strategies: the identification of a coordinated response to the challenge and the opportunity presented by the sixth amendment to the cosmetics directive (76/768/EEC). The report and recommendations of ECVAM workshop 7. ATLA23, 398–409.
89.
TichiasK., FentemJ., BasketterD., BothamP., BrookerP., BrunerL., EvansP., FairhurstS., FassoldE., FielderR., GerberickF., HarveyP., KoeterH., ParsonsP., SchledeE., ShannonD., & SpielmannH. (1998). Progress in toxicological testing: reduction and refinement issues. Recommendations from a joint UK Government/ECVAM meeting. ATLA26, 619–627.
90.
BruceR.B. (1985). An Up-and-Down Procedure for acute toxicity testing. Fundamental and Applied Toxicology5, 151–157.
91.
Van den HeuvalM.J., ClarkD.G., FielderR.J., KoundakjianP.P., OliverG.J.A., PellingD., TomlinsonN.J., & WalkerA.P. (1990). The international validation of a fixed-dose procedure as an alternative to the classical LD50 test. Food and Chemical Toxicology28, 469–482.
92.
OECD (1996). OECD Guidelines for the Testing of Chemicals No. 423: Acute Oral Toxicity — Acute Toxic Class Method, 15 pp. Paris, France: OECD.
93.
FielderR.J., GauntI.F., RhodesC., SullivanF.M., & SwanstonD.W. (1987). Hierarchical approach to the assessment of dermal and ocular irritancy: a report by the British Toxicology Society Working Party on Irritancy. Human and Experimental Toxicology6, 269–278.
94.
van de SandtJ., RoguetR., CohenC., EsdaileD., PonecM., CorsiniE., BarkerC., FusenigN., LiebschM., BenfordD., de Brugerolle de FraissinetteA., & FartaschM. (1999). The use of human keratinocytes and human skin models for predicting skin irritation. The report and recommendations of ECVAM workshop 38. ATLA27, 723–743.
95.
ZuangV., BallsM., BothamP.A., CoquetteA., CorsiniE., CurrenR.D., ElliottG.R., FentemJ.H., HeylingsJ.R., LiebschM., MedinaJ., RoguetR., van de SandtJ.J.M., WiemannC., & WorthA.P. (2002). Follow-up to the ECVAM prevalidation study on in vitro tests for acute skin irritation. ATLA30, 109–129.
96.
NIH (2001). Report of the International Workshop on In Vitro Methods for Assessing Acute Systemic Toxicity, 158 pp. Research Triangle Park, NC, USA: NIEHS.
97.
SpielmannH., GenschowE., LiebschM., & HalleW. (1999). Determination of the starting dose for acute oral toxicity (LD50) testing in the Up-and-Down Procedure (UDP) from cytotoxicity data. ATLA27, 957–966.
98.
NIH (2002). Guidance Document on Using In Vitro Data to Estimate In Vivo Starting Doses for Acute Toxicity.Research Triangle Park, NC, USA: NIEHS.
99.
ZeigerE. (2001). Genetic toxicity tests for predicting carcinogenicity. In Genetic Toxicology and Cancer Risk Assessment (ed. ChoyW.N.), pp. 29–46. New York, NY, USA: Marcel Dekker.
100.
MitchellI. de G., & CombesR.D. (1997). In vitro genotoxicity and cell transformation assessment. In In Vitro Methods in Pharmaceutical Research (ed. CastellJ.V., & Gómez-LechónM.J.), pp. 318–352. London, UK: Academic Press Ltd.
101.
CombesR.D. (1995). Regulatory genotoxicity testing: a critical appraisal. ATLA23, 352–379.
102.
CombesR.D. (1992). The in vivo relevance of in vitro genotoxicity assays incorporating enzyme activation systems. In Progress in Drug Metabolism, Vol. 13 (ed. GibsonG.G.), pp. 295–321. London, UK: Taylor and Francis.
103.
CrespiC. (1995). Use of genetically engineered cells for genotoxicity testing. In Environmental Mutagenesis (ed. PhillipsD.H., & VenittS.), pp. 233–260. Oxford, UK: Bios Scientific Publishers.
104.
MacéK., OffordE.A., & PfeiferA.M.A. (1997). Drug metabolism and carcinogen activation studies with human genetically engineered cells. In In Vitro Methods in Pharmaceutical Research (ed. CastellJ.V., & Gómez-LechónM.J.), pp. 433–456. London, UK: Academic Press.
JosephyP.D., EvansD.H., ParikhA., & GuengerichF.P. (1998). Metabolic activation of aromatic amine mutagens by simultaneous expression of human cytochrome P450 1A2, NADPH-cytochrome P450 reductase, and N-acetyltransferase in Escherichia coli.Chemical Research in Toxicology11, 70–74.
107.
AshbyJ., & TennantR.W. (1991). Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicals tested by the US NTP: structure–activity relationships for skin sensitization: an expert system. Mutation Research257, 229–306.
108.
ChoyW.N. (2001). Genotoxic and nongenotoxic mechanisms of carcinogenesis. In Genetic Toxicology and Cancer Risk Assessment (ed. ChoyW.N), pp. 47–72. New York, NY, USA: Marcel Dekker
109.
TennantR.W., StasiewiczS., MennearJ., FrenchJ.E., & SpaldingJ.W. (1999). Genetically altered mouse models for identifying carcinogens. In The Use of Short- and Medium-Term Tests for Carcinogens and Data on Genetic Effects in Carcinogenic Hazard Evaluation (ed. McGregorD.B., RiceJ.M., & VenittS.), pp. 123–150. Lyon, France: IARC.
110.
van ZellerA-M., & CombesR.D. (1999). Transgenic mouse bioassays for carcinogenicity testing: a step in the right direction?ATLA27, 839–846.
111.
Anon. (2001). An evaluation of alternatives to carcinogenicity testing. Toxicologic Pathology29, S5.
112.
CombesR.D. (1997). Detection of nongenotoxic carcinogens: major barriers to replacement of the rodent bioassay. In Animal Alternatives, Welfare and Ethics (ed. van ZutphenL.F.M., & BallsM.), pp. 627–634. Amsterdam, The Netherlands: Elsevier.
113.
CombesR., BallsM., CurrenR., FischbachM., FusenigN., KirklandD., LasneC., LandolphJ., LeBoeufR., MarquardtH., McCormickJ., MüllerL., RivedalE., SabbioniE., TanakaN., VasseurP., & YamasakiH. (1999). Cell transformation assays as predictors of human carcinogenicity. The report and recommendations of ECVAM Workshop 39. ATLA27, 745–767.
114.
TsuchiyaT., UmedaM., NishiyamaH., YoshimuraI., AjimiS., AsakuraM., BabaH., DewaY., EbeY., FushiwakiY., HamadaS., HamamuraT., HayashiM., IwasaY., KajiwaraY., KsaharaY., KawabataM., KitadaE., KuboK., MashikoK., MiuraD., MizuhashiF., MizunoF., NakajimaM., NakamuraY., NobeN., OishiH., OtaE., SakaiA., SatoM., ShimadaS., SugiyamaT., TakahashiC., TakedaY., TanakaN., ToyoizumiC., TsutsuiT., WakuriS., YajimaS., & YajimaN.(1999). An interlaboratory validation study of the improved transformation assay employing Balb/c 3T3 cells: results of a collaborative study on the two-stage cell transformation assay by the Non-genotoxic Carcinogen Study Group. ATLA27, 685–702.
115.
CombesR.D. (2000). Endocrine disruptors — a critical review of in vitro and in vivo testing strategies for assessing their toxic hazard to humans. ATLA28, 81–118.
116.
Committee on Mutagenicity of Chemicals in Food, Consumer Products and the Environment (2000). Guidance on a Stategy for Testing of Chemicals for Mutagenicity, 40 pp. London, UK: Department of Health. Web site http:\\www.doh.gov.uk/com/guidance.pdf (Accessed 8.8.02).
117.
ParryE.M., & ParryJ.M. (1995). In vitro cytogenetics and aneuploidy. In Environmental Mutagenesis (ed. PhillipsD.H., & VenittS.), pp. 121–139. Oxford, UK: Bios Scientific Publishers.
118.
StopperH., & MüllerS.O. (1997). Micronuclei as a biological endpoint for genotoxicity: a minireview. Toxicology in Vitro11, 661–667.
119.
AardemaM.J., & Kirsch-VoldersM. (2001). The in vitro micronucleus assay. In Genetic Toxicology and Cancer Risk Assessment (ed. ChoyW.N), pp. 163–186. New York, NY, USA: Marcel Dekker.
120.
CombesR.D., StopperH., & CasparyW.J. (1995). The use of L5178Y mouse lymphoma cells to assess the mutagenic, clastogenic and aneugenic properties of chemical. Mutagenesis5, 403–408.
121.
CombesR.D. (1991). Use of clinical samples for biomonitoring of genotoxic exposure to pharmaceuticals. In Clinical Measurement in Drug Evaluation (ed. NimmoW.), pp. 173–191. London, UK: Wolfe Medical Publications Limited.
122.
CombesR.D., AndersonD., BrooksT., NealeS., & VenittS. (1984). The detection of mutagens in urine, faeces and body fluids. In Guidelines for Mutagenicity Testing, Part II, Supplementary Tests, Mutagens in Body Fluids and Excreta, Nitrosation Products (ed. DeanB.J.), pp. 203–244. Swansea, UK: United Kingdom Environmental Mutagen Society.
123.
IARC (1993). IARC Monographs, Vol. 57: Evaluation of Carcinogenic Risk to Humans: Occupational Exposures to Hairdressers and Barbers and Personal Use of Hair Colorants; Some Hair Dyes, Cosmetic Colorants, Industrial Dyestuffs and Aromatic Amines, 427 pp. Lyon, France: IARC.
124.
BabishJ.G., ScarlettJ.M., VoeklerS.E., GutenmannW.H., & LiskD.J. (1991). Urinary mutagens in cosmetologists and dental personnel. Journal of Toxicology and Environmental Health34, 197–206.
125.
AtterwillC.K., BruininkA., DrejerJ., DuarteE., McFarlane AbdullaE., MeredithC., NicoteraP., ReganC., Rodrigues-FarreE., SimpsonM.G., SmithR., VeronesiB., VijverbergH., WalumE., & WilliamC.D. (1994). In vitro neurotoxicity testing. The report and recommendations of ECVAM workshop 3. ATLA22, 350–362.
126.
PentreathV.W. ed. (1999). Neurotoxicology In Vitro, 291 pp. London, UK: Taylor & Francis.
127.
PentreathV.W., & AtterwillC.K. (1996). An in vitro neurotoxicity testing scheme: evaluation of cytotoxicity determinations in neural and non-neural cells. In Vitro Toxicology9, 83–92.
128.
WilliamsS.P., O'BrienS., WhitmoreK., PurcellW.H., CooksonM.R., MeadC., PentreathV.W., & AtterwillC.K. (1996). An in vitro neurotoxicity testing scheme: evaluation of cytotoxicity determinations in neural and non-neural cells. In Vitro Toxicology9, 83–92.
129.
AtterwillC.K., & PurcellW.M. (1999). Brain spheroid and other organotypic culture systems in vitro neurotoxicology. In Neurotoxicology In Vitro (ed PentreathV.W.), pp. 213–238. London, UK: Taylor & Francis.
130.
LatteraJ., BresslerJ.P., IndurtiR.R., Belloni-OliviL., & GoldsteinG.W. (1992). Inhibition of astroglia-induced endothelial differentation by inorganic lead: a possible role for protein kinase C. Proceedings of the National Academy of Sciences, USA89, 10748–10752.
131.
VeronesiB., & EhrichM. (1999). Cell culture models of environmental chemical neurotoxicity. In Neurotoxicology In Vitro (ed PentreathV.W.), pp. 239–268. London, UK: Taylor & Francis.
132.
BruininkA., ZimmermannG., & ReisenF. (1991). Neurotoxic effects of chloroquine in vitro.Archives of Toxicology65, 480–484.
133.
BruininkA., MillerJ., Shah-DerlerB., SidlerC., ReiserP., BirchlerT., RasonyiT., & ZimmermannG. (1994). A serum-free neurotoxicity screening system using embryonic chick cells (SCENT). Toxicology Letters74, Suppl. 1, 10–17.
134.
BlaauboerB.J., BaylissM.K., CastellJ.V., EveloC.T.A., FrazierJ.M., GroenK., GuldenM., GuillouzoA., HissinkA.M., HoustonJ.B., JohansonG., de JonghJ., KedderisG.L., ReinhartC.A., van de SandtJ.J.M., & SeminoG. (1996). The use of biokinetics and in vitro methods in toxicological risk evaluation. The report and recommendations of ECVAM workshop 15. ATLA24, 473–497.
135.
WalumE., BallsM., BianchiV., BlaauboerB., BolcsfoldiG., GuillouzoA., MooreG.A., OdlandL., ReinhartC., & SpielmannH. (1992). ECITTS: an integrated approach to the application of in vitro tests systems to the hazard assessment of chemicals. ATLA, 20, 406–428.
136.
BallsM., & WalumE. (1999). Towards the acceptance of in vitro neurotoxicity tests. In Neurotoxicology In Vitro (ed. PentreathV.W.), pp. 26–28. London, UK: Taylor & Francis.
137.
DeJonghJ., ForsbyA., HoustonJ.B., BeckmanM., CombesR., & BlaauboerB.J. (1999). An integrated approach to the prediction of systemic toxicity using computer-based biokinetic models and biological in vitro test methods: overview of a prevalidation study based on the ECITTS project. Toxicology in Vitro13, 549–554.
138.
BlaauboerB.J., BarrattM.D., & HoustonJ.B. (1999). The integrated use of alternative methods in toxicological risk evaluation. ECVAM integrated testing stategies task force report 1. ATLA27, 229–237.
139.
RogiersV., BallsM., BasketterD., BerardescaE., EdwardsC., ElsnerP., EnnenJ., LévêqueJ-L., LódenM., MassonP., ParraJ., PayeM., PiérardG., RodriguesL., SchaeferH., SalterD., & ZuangV. (2000). The potential use of non-invasive methods in the safety assessment of cosmetic products. The report and recommendations of ECVAM/ EEMCO workshop 36. ATLA27, 515–537.
140.
FryJ., & GeorgeE. (2001). In vitro toxicology in the light of new technologies. ATLA29, 745–748.
141.
BakerV. (2001). Endocrine disruptors — testing strategies to assess human hazard. Toxicology in Vitro15, 413–419.
142.
BrownN.A., SpielmannH., BechterR., FlintO.P., FreemanS.J., JelinekR.J., KochE., NauH., NewallD.R., PalmerA.K., RenaultJ-Y., RepettoM., VogelR., & WigerR. (1995). Screening chemicals for reproductive toxicity: the current alternatives. The report and recommendations of an ECVAM/ETS workshop (ECVAM workshop 12). ATLA23, 868–882.
143.
SpielmannH., PohlI., DoringB., LiebschM., & MoldenhauerF. (1997). The embryonic stem cell test (EST), an in vitro embryotoxicity test using two permanent mouse cell lines: 3T3 fibroblasts and embryonic stem cells. Toxicology in Vitro10, 119–127.
144.
GenschowE., ScholzG., BrownN., PiersmaA., BradyM., ClemannN., HuuskonenH., PaillardF., BremerS., BeckerK., & SpielmannH. (2000). Development of prediction models for three in vitro embryotoxicity tests in an ECVAM validation study. In Vitro and Molecular Toxicology13, 15–65.
145.
GenschowE., SpielmannH., ScholzG., SellerA., BrownN., PiersmaA., BradyM., ClemannN., HuuskonenH., PaillardF., BremerS., & BeckerK. (2002). The ECVAM International Validation Study on In Vitro Embryotoxicity Tests: results of the definitive phase and evaluation of prediction models. ATLA30, 151–176.
146.
OECD (1995). OECD Guideline for Testing of Chemicals. Adopted by the Council on 27th July 1995. Reproduction/Developmental Toxicity Test, 10 pp. Paris, France: OECD. Web site http://www1.oecd.org/ehs/chemtest/E421.pdf (Accessed 8.8.02).
147.
OECD (1996). OECD Guideline for Testing of Chemicals. Combined Repeated Dose Toxicity Study with the Reproduction/Development Toxicity Screening Test, 14 pp. Paris, France: OECD. Web site http://www1.oecd/ehs/chemtest/E422.pdf (Accessed 8.8.02).
148.
MillerK., & MeredithC. (2000). Immunotoxicology. In General and Applied Toxicology, 2nd edn (ed. BallantyneB., MarrsT.C., & SyversenT.), pp. 997–1015. London, UK: Macmillan.
149.
KimberI. (2000). Skin sensitisation: immunological mechanisms and novel approaches to predictive testing. In Progress in the Reduction, Refinement and Replacement of Animal Experimentation (ed. BallsM., van ZellerA-M., & HalderM.E.), pp. 613–622. Amsterdam, The Netherlands: Elsevier.
150.
KimberI., PichowskiJ.S., BettsC.J., Cumber-batchM., BasketterD.A., & DearmanR.J. (2001). Alternative approaches to the identification and characterisation of chemical allergens. Toxicology in Vitro15, 307–312.
151.
CloseB., CombesR., HubbardA., & IllingworthJ. eds (1997). Volunteers in Research and Testing, 198 pp. London, UK: Taylor & Francis.
152.
MassonP. (1999). The contribution of the European Cosmetics Directive towards international harmonisation: impact on the evaluation of safety and efficacy. In Cosmetics: Controlled Efficacy Studies and Regulation (ed. ElsnerP., MerkH.F., & MaibachH.I.), pp. 20–35. Berlin, Germany: Springer.
153.
OrmeM. (1997). The risks of studies in healthy volunteers. In Volunteers in Research and Testing (ed. CloseB., CombesR., HubbardA., & IllingworthJ.), pp. 99–108. London, UK: Taylor & Francis.
CombesR.D. (2002). The EU White Paper: Strategy for a Future Chemicals Policy (an idea that must have seemed good at the time!)ATLA30, 1–3.
156.
WorthA.P., & BallsM. eds (2002). Alternative (non-animal) methods for chemicals testing: current status and future prospects. A report prepared by ECVAM and the ECVAM working group on chemicals. ATLA30, Suppl. 1, 1–125.
157.
SabbioniE., & BallsM. (1995). Use of cell cultures and nuclear and radioanalytical techniques for environmental, occupational and biomedical metal toxicology research at the JRC, Ispra. In The World Congress on Alternatives and Animal Use in the Life Sciences: Education, Research, Testing (ed. GoldbergA.M., & van ZutphenL.F.M.), pp. 101–108. New York, NY, USA: Mary Ann Liebert.
158.
WalkerC.H. (1998). Alternative approaches and tests in ecotoxicology: a review of the present position and the prospects for change, taking into account ECVAM's duties, topic selection and test criteria. ATLA26, 649–677.
159.
WalkerC., KaiserK., KleinW., LagadicL., PeakallD., SheffieldS., SoldanT., & YasunoM. (1998). 13th meeting of the Scientific Group on Methodologies for the Safety Evaluation of Chemicals (SGOMSEC): alternatives testing methodologies for ecotoxicity. Environmental Health Perspectives106, 441–451.
160.
HillE.F. (1999). Wildlife toxicology. In General and Applied Toxicology, 2nd edn (ed. BallantyneB., MarrsT.C., & SyversenT.), pp. 1327–1363. London, UK: Macmillan Reference.
161.
BottrillK. (1998). The use of biomarkers as alternatives to current animal tests on food chemicals. ATLA26, 421–480.
162.
RepettoG., JosA., HazenM.J., MoleroM.L., del PesoA., SlagueroM., del CastilloP., Rodriquez-VicenteM.C., & RepettoM. (2001). A test battery for the ecotoxicological evaluation of penta-chlorophenol. Toxicology in Vitro15, 503–509.
163.
BentleyA., AtkinsonA., JezekJ., & RawsonD.M. (2001). Whole cell biosensors — electrochemical and optical approaches to ecotoxicity testing. Toxicology in Vitro15, 469–475.
164.
KaiserK.L.E., & PalabriciaV.S. (1991). Photo-bacterium phosphoreum toxicity data index. Journal of Water Pollution Research26, 361–431.
165.
BallsM., GoldbergA.M., FentemJ.H., BroadheadC.L., BurchR.L., FestingM.F.W., FrazierJ.M., HendriksenC.F.M., JenningsM., van der KampM.D.O., MortonD.B., RowanA.N., RussellC., RussellW.M.S., SpielmannH., StephensM.L., StokesW.S., StraughanD.W., YagerJ.D., ZurloJ., & van ZutphenB.F.M. (1995). The Three Rs: the way forward. The report and recommendations of ECVAM workshop 11. ATLA23, 838–866.
166.
LangleyG. (2000). Replacing animals in medical research. In Progress in the Reduction, Refinement and Replacement of Animal Experimentation (ed. BallsM., van ZellerA-M., and HalderM.E.), pp. 639–650. Amsterdam, The Netherlands: Elsevier.
167.
van ZutphenL.F.M., BaumansV., & BeynenA.C. eds (2001). Principles of Laboratory Animal Science, 416 pp. Amsterdam, The Netherlands: Elsevier.
168.
RadfordM. (2001). Animal Welfare Law in Britain, 441 pp. , Oxford, UK: Oxford University Press.
169.
MephamT.B., CombesR.D., BallsM., BarvieriO., BlokhuisH.J., CostaP., CrillyR.E., de Cock BuningT., DelpireV.C., O'HareM.J., HoudebineL-M., van KreijlC.F., van der MeerM., ReinhardtC.A., WolfE., & van ZellerA-M., (1998). The use of transgenic animals in the European Union. The report and recommendations of ECVAM workshop 28. ATLA26, 21–43.
170.
JenkinsE.S., & CombesR.D. (2000). FRAME's response to an APC questionnaire on emerging biotechnologies and The Animals (Scientific Procedures) Act 1986.ATLA28, 333–338.
171.
CombesR.D. (1999). Summary of discussion: in vitro models for investigation of chronic toxicity and reversibility. Toxicology in Vitro13, 853–857.
172.
PfallerW., BallsM., ClothierR., CoeckeS., DierickxP., EkwallB., HanleyB.A., HartungT., PrietoT., RyanM.P., SchmuckG., SladowskiD., VericatJ-A., WendelA., WolfA., & ZimmerJ. (2001). Novel advanced in vitro methods for long-term toxicity testing: the report and recommendations of ECVAM workshop 45. ATLA29, 393–426.
173.
ScheersE.M., EkwallB., & DierickxP.J. (2001). In vitro long-term cytotoxicity testing of 27 MEIC chemicals on Hep G2 cells and comparison with acute human toxicity data. Toxicology in Vitro15, 153–161.